Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals

AIDS

Volumn 23, Issue 13, 2009, Pages 1707-1715

  Matthews, Gail V ^a   Seaberg, Eric ^b   Dore, Gregory J ^a   Bowden, Scott ^c   Lewin, Sharon R ^d   Sasadeusz, Joe ^c   Marks, Pip ^a   Goodman, Zachary ^e   Philp, Frances H ^f   Tang, Yiwei ^b   Locarnini, Stephen ^c   Thio, Chloe L ^f  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^d ALFRED HOSPITAL   (Australia)

^e ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral therapy; Hepatitis B; HIV infection; Liver disease

Indexed keywords

EMTRICITABINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR; VIRUS DNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRAL GENETICS;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; DNA, VIRAL; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MUTATION; VIRAL LOAD;

EID: 69449101509     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832b43f2     Document Type: Article

References (27)

1. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:593-601. (Pubitemid 40543982)
2. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, Thomas DL. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926.
3. Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42:799-805. (Pubitemid 40693195)
4. Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000; 24:211-217. (Pubitemid 30748924)
5. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334:1422-1427. (Pubitemid 26157437)
6. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34:411-416. (Pubitemid 32702355)
7. Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5:890-897. (Pubitemid 47127032)
8. Brook MG, Gilson R, Wilkins E. BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis B virus infection (2005). HIV Med 2005; 6 (Suppl 2):84-95.
9. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, November 3, 2008. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
10. Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, Rockstroh J, et al. Care of patients with chronic hepatitis B and HIV coinfection: recommendations from an HIV-HBV International Panel. AIDS 2005; 19:221-240. (Pubitemid 40396554)
11. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539.
12. Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von Boemmel F, et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006; 20:1951-1954. (Pubitemid 44427612)
13. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987; 126:310-318. (Pubitemid 17102758)
14. Dudley J, Jin S, Hoover D, Metz S, Thackeray R, Chmiel J. The Multicenter AIDS Cohort Study: retention after 9 1/2 years. Am J Epidemiol 1995; 142:323-330.
15. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357:1069-1075. (Pubitemid 32322537)
16. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-1325. (Pubitemid 43980111)
17. Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20:863-870. (Pubitemid 43731568)
18. Gunther S, Li BC, Miska S, Kruger DH, Meisel H, Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995; 69:5437-5444.
19. Yuen LK, Ayres A, Littlejohn M, Colledge D, Edgely A, Maskill WJ, et al. SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B. Antiviral Res 2007; 75:64-74. (Pubitemid 46621069)
20. Nelson M, Bhagani S, Fisher M, Leen C, Brook G, Mandalia S, et al. A 48 week study of tenofovir DF (TDF) or lamivudine (LAM) or a combination of tenofovir and lamivudine for the treatment of chronic hepatitis B in HIV/hepatitis B co-infected individuals. 13th Conference on Retrovirus and Opportunistic Infections. Denver, USA; 2006.
21. Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat P, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 2008; 48:1062-1069.
22. White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65RRM184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 2002; 46:3437-3446. (Pubitemid 35192909)
23. Miller MD, Anton KE, Mulato AS, Lamy PD, Cherrington JM. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J Infect Dis 1999; 179:92-100.
24. Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10:727-734. (Pubitemid 41376852)
25. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45:307-313. (Pubitemid 46374587)
26. Maida I, Soriano V, Castellares C, Ramos B, Sotgiu G, Martin-Carbonero L, et al. Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activity. HIV Clin Trials 2006; 7:246-250. (Pubitemid 44963808)
27. Jain MK, Opio CK, Osuagwu CC, Pillai R, Keiser P, Lee WM. Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy? Clin Infect Dis 2007; 44:996-1000.